(Q40995343)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

review article

1 reference

title

The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1 reference

Helicobacter pylori infectious disease

1 reference

N Vakil

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

B Fennerty

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

language of work or name

English

0 references

publication date

1 May 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

16 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

issue

5A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

page(s)

60S-63S; discussion 63S-64S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada

16 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980230-0

Can overall results of clinical trials be applied to all patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980230-0

Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980230-0

Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980230-0

High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980230-0

Therapeutic-class wars--drug promotion in a competitive marketplace

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980230-0

Why some health policies don't make sense at the bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980230-0

Factors influencing the eradication of Helicobacter pylori with triple therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2980230-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(96)80230-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8644784%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1 reference